FOLH1 and prostate carcinoma: In the study of Zang et al. 28 patients with prostate cancer received up to three cycles of [177Lu]Lu-EB-PSMA-617 treatment with different doses in each of three groups (1.2 GBq, 2.1 GBq and 3.5 GBq, respectively).